# US 10,119,132 B2 · Long-acting coagulation factors and methods of producing same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,119,132 B2
- Document ID: US10119132B2
- Status: Granted
- Kind: B2
- Application number: 14/948,890
- Filed: 2015-11-23
- Published: 2016-03-17
- Granted: 2018-11-06
- Earliest claimed: 2009-07-09
- Assignees: OPKO Biologics Ltd.
- Applicants: OPKO Biologics Ltd.
- Inventors: Udi Eyal Fima; Gili Hart
- Web page: https://patentgrep.com/patent/US10119132B2

## CPC

- C12N 9/6437: {Coagulation factor VIIa (3.4.21.21)}
- C07K 14/505: Erythropoietin [EPO]
- C07K 14/59: Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
- C07K 14/745: Blood coagulation or fibrinolysis factors
- C12N 9/644: {Coagulation factor IXa (3.4.21.22)}
- C12N 9/96: Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
- C12Y 304/21021: Coagulation factor VIIa (3.4.21.21)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 38/4846: {Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)}
- C07K 2319/31: fusions, other than Fc, for prolonged plasma life, e.g. albumin
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to the carboxy terminus but not to the amino terminus of a coagulation factor and polynucleotides encoding the same are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using and producing same are also disclosed.

## Claims

### Claim 1

A method of treating hemophilia A in a subject, the method comprising administering a CTP-modified Factor VII (FVII) polypeptide to said subject, wherein said CTP-modified Factor VII (FVII) polypeptide consists of a coagulation Factor VII (FVII) polypeptide and three chorionic gonadotropin carboxy terminal peptides (CTPs) attached to the carboxy terminus of said coagulation FVII polypeptide, thereby treating said hemophilia A.

### Claim 2 (depends on 1)

The method of claim 1, wherein at least one CTP consists of the amino acid sequence selected from the group consisting of: SEQ ID NO: 1 and SEQ ID NO: 2.

### Claim 3 (depends on 1)

The method of claim 1, wherein at least one CTP is glycosylated.

### Claim 4 (depends on 1)

The method of claim 1, wherein at least one CTP is attached to said coagulation Factor VII polypeptide via a linker.

### Claim 5 (depends on 4)

The method of claim 4, wherein said linker is a peptide bond.

### Claim 6 (depends on 1)

The method of claim 1, wherein the sequence of said CTP-modified FVII polypeptide is selected from the group consisting of SEQ ID NO: 25 and SEQ ID NO: 46.

### Claim 7 (depends on 1)

The method of claim 1, wherein said coagulation FVII polypeptide is an activated coagulation FVII (FVIIa) polypeptide.

### Claim 8 (depends on 7)

The method of claim 7, wherein said activated coagulation FVII polypeptide is in the form of a disulfide-linked two chain heterodimer.

### Claim 9 (depends on 1)

The method of claim 1, wherein the subject is a human child.

### Claim 10 (depends on 1)

The method of claim 1, wherein said administering is via the subcutaneous route.

### Claim 11

A method of treating hemophilia B in a subject, the method comprising the step of administering to the subject a CTP-modified Factor IX (FIX) polypeptide, wherein the CTP-modified Factor IX (FIX) polypeptide consists of a coagulation Factor IX (FIX) polypeptide and three chorionic gonadotrophin carboxy terminal peptides (CTPs) attached to the carboxy terminus of said coagulation FIX polypeptide, thereby treating said hemophilia B in said subject.

### Claim 12 (depends on 11)

The method of claim 11, wherein the sequence of said CTP-modified Factor IX (FIX) polypeptide is selected from the group consisting of SEQ ID NO: 31 and SEQ ID NO: 48.

### Claim 13 (depends on 11)

The method of claim 11, wherein at least one CTP consists of the amino acid sequence selected from the group consisting of: SEQ ID NO: 1 and SEQ ID NO: 2.

### Claim 14 (depends on 11)

The method of claim 11, wherein at least one CTP is glycosylated.

### Claim 15 (depends on 11)

The method of claim 11, wherein at least one CTP is truncated.

### Claim 16 (depends on 11)

The method of claim 11, wherein at least one CTP is attached to said coagulation FIX polypeptide via a linker.

### Claim 17 (depends on 16)

The method of claim 16, wherein said linker is a peptide bond.

### Claim 18 (depends on 11)

The method of claim 11, wherein said coagulation FIX polypeptide is an activated coagulation FIX (FIXa) polypeptide.

### Claim 19 (depends on 18)

The method of claim 18, wherein said activated coagulation FIX polypeptide is in the form of a disulfide-linked two chain heterodimer.

### Claim 20 (depends on 11)

The method of claim 11, wherein the subject is a human child.

### Claim 21 (depends on 11)

The method of claim 11, wherein said administering is via the subcutaneous route.
